Merck states, "Moreover, a price increase for the coming year was typically negotiated. It was agreed to increase by agreed percentage points both the list price for MG (established anew annually), which applied at least in Europe to smaller customers (share of only approximately 10 % of turnover), as well as the individually-negotiated prices applicable to larger customers (key accounts). As a consequence, the list prices of Merck and Aventis were - aside from insubstantial deviations - in effect the same"(54).
Recital 84, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002